Welcome to D3 Pharma
D3 Pharma is a privately owned specialty pharmaceutical company based in the United Kingdom.
It is committed to the research, development and commercialisation of licensed high-strength vitamin D medicinal products for the treatment of vitamin D deficiency, insufficiency and associated conditions.
D3 Pharma’s pioneering work in the vitamin D deficiency area aims to address a significant unmet need and improve product access in the UK, Europe and worldwide. Our goal is to provide physicians, nutritionists and other healthcare professionals with high-quality, high-strength, clinically effective vitamin D3 products that can be used to provide rapid repletion and maintenance of vitamin D levels in both children and adults. Our high-strength product range (Plenachol) will include vitamin D3 (cholecalciferol) at oral doses of 20,000 and 40,000 International Units (IU).
For information regarding D3 Pharma's Specials product supply, please e-mail ops.orders@oxfordhealth.nhs.uk or Fax: 01865321090, quoting the catalogue number below:
Catalogue no.: VIT004 - Plenachol (Cholecalciferol) 20,000 IU Capsules
Catalogue no.: VIT005 - Plenachol (Cholecalciferol) 40,000 IU Capsules
Plenachol Product Summary
- Produced in the UK to GMP in a MHRA licensed facility
- Suitable for vegetarians
- Halal
- Free from peanut constituents
- Gelatin-free
- Soya-free
- Long shelf-life
- Fully tested - Certificate of Analysis available on request
News
19 June 2012
D3 Pharma Limited today announces its
continuing partnership with Encap Drug Delivery to expedite the commercial
manufacturing and product licensing programme for its proprietary high-dose
oral vitamin D3 product, Plenachol, for the treatment of
vitamin D deficiency and insufficiency. Plenachol is
a patented liquid-filled capsule formulation of vitamin D3 which was developed
in conjunction with Encap and is available at two dose-strengths: 20,000
and 40,000 units. Plenachol has a
unique formulation base which is free from animal derived excipients and peanut
constituents. The utility of Encap’s world-class capsule liquid-filling
technology secures Plenachol as a first and best-in-class
high-dose oral vitamin D3 product.
Plenachol will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery. For more information regarding PlenacholTM Specials supply please contact: Dr Janice McLachlan JMcLachlan@encapdrugdelivery.com
26 May 2012
D3 Pharma today announces the launch
of Plenachol (Cholecalciferol) 40,000 IU Capsules.
For further information please contact D3 Pharma at enquiries@d3-pharma.com
19 March 2012
D3 Pharma products now available through the
NHS Oxford Pharmacy Store for next day delivery.
To place an order, please e-mail ops.orders@oxfordhealth.nhs.uk or Fax: 01865321090
Catalogue no.: VIT004 - Plenachol (Cholecalciferol) 20,000 IU
Capsules
Catalogue no.: VIT005 - Plenachol (Cholecalciferol) 40,000 IU
Capsules
22 February 2012
D3 Pharma today announces the
completion of a Collaborative Agreement with a major European Pharmaceutical
Company to expedite the development and commercialisation of its patented
high-dose oral Vitamin D3 (Cholecalciferol) products in the UK and other
European territories. This collaboration will further enable D3 Pharma to
develop its expanding portfolio of products with a new range of paediatric
vitamin D formulations tailored towards the specific clinical needs of the
paediatric population.
D3 Pharma is committed to providing global access to licensed Vitamin D3 medicines for the treatment of vitamin D deficiency, insufficiency and developing associated diseases.
18 February 2012
D3 Pharma informs the pharmacy
community of the availability of its products with a letter to the
Pharmaceutical Journal.
Ref: Pharmaceutical Journal, Volume 288, Page 203
